Two US drug safety reviewers have recommended that GlaxoSmithKline PLC’s diabetes drug Avandia be pulled from the market after concluding it is more dangerous to the heart than a rival medicine, documents released on Saturday show.
The US Food and Drug Administration (FDA) will again ask an advisory panel to consider the risks of the drug, which was Glaxo’s second-biggest-selling product before questions about a possible link to heart attacks emerged in 2007.
US Senators Max Baucus and Charles Grassley meanwhile released a report saying evidence suggested Glaxo knew of possible cardiac risks associated with Avandia years before the issue became public.
“I await the recommendations of the advisory committee,” FDA Commissioner Margaret Hamburg said in a statement.
“Meanwhile, I am reviewing the inquiry made by Senators Baucus and Grassley and I am reaching out to ensure that I have a complete understanding and awareness of all of the data and issues involved,” she said.
In an October 2008 memo released by the senators, FDA reviewers David Graham and Kate Gelperin concluded “the risks of [Avandia] are serious and exceed those for” Takeda Pharmaceutical Co’s competitor Actos.
They said there was “strong evidence that [Avandia] confers an increased risk of” heart attack and heart failure when compared with Actos.
They estimated that 500 more heart attacks and 300 cases of heart failure were occuring every month with use of Avandia instead of Actos, based on levels of use at the time of their memo.
Graham, an outspoken critic of the FDA’s handling of drug risks, had argued to an advisory panel in 2007 that Avandia sales should be stopped. The panel voted 22-1 to urge the FDA to keep the drug on the market.
Glaxo said in a statement “the scientific evidence simply does not establish” that Avandia increases risks of cardiovascular problems such as heart attacks.
Sales of Avandia, known generically as rosiglitazone, topped US$3 billion in 2006 but fell to US$1.2 billion last year.
The FDA decided in November 2007 that Avandia should carry a warning saying a review of 42 studies associated the drug with an increased risk of a heart attack or chest pain compared with a placebo.
However, it said overall data were “inconclusive.”
Concerns about Avandia emerged in May 2007 when Cleveland Clinic researchers published a study saying that there was a link between the drug and heart attacks.
The senators’ report said evidence reviewed by investigators on the Senate Finance Committee, which Baucus chairs, showed Glaxo “knew for several years prior to this study that there were possible cardiac risks associated with Avandia.”
Glaxo executives “attempted to intimidate independent physicians, focused on strategies to minimize or misrepresent findings that Avandia may increase cardiovascular risk and sought ways to downplay findings that a competing drug might reduce cardiovascular risk,” the report said.
Committee staff reviewed more than 250,000 documents provided by Glaxo, the FDA and others, the report said. Anonymous whistleblowers provided hundreds of other pages.
The New York Times first reported on the memo from FDA reviewers and the senators’ report on Friday night on its Web site.
Glaxo said it rejected the report’s conclusions. The company said the report “cherry-picks information from documents, which mischaracterizes GlaxoSmithKline’s comprehensive efforts to research Avandia and communicate those findings to regulators, physicians and patients.”
MORE VISITORS: The Tourism Administration said that it is seeing positive prospects in its efforts to expand the tourism market in North America and Europe Taiwan has been ranked as the cheapest place in the world to travel to this year, based on a list recommended by NerdWallet. The San Francisco-based personal finance company said that Taiwan topped the list of 16 nations it chose for budget travelers because US tourists do not need visas and travelers can easily have a good meal for less than US$10. A bus ride in Taipei costs just under US$0.50, while subway rides start at US$0.60, the firm said, adding that public transportation in Taiwan is easy to navigate. The firm also called Taiwan a “food lover’s paradise,” citing inexpensive breakfast stalls
TRADE: A mandatory declaration of origin for manufactured goods bound for the US is to take effect on May 7 to block China from exploiting Taiwan’s trade channels All products manufactured in Taiwan and exported to the US must include a signed declaration of origin starting on May 7, the Bureau of Foreign Trade announced yesterday. US President Donald Trump on April 2 imposed a 32 percent tariff on imports from Taiwan, but one week later announced a 90-day pause on its implementation. However, a universal 10 percent tariff was immediately applied to most imports from around the world. On April 12, the Trump administration further exempted computers, smartphones and semiconductors from the new tariffs. In response, President William Lai’s (賴清德) administration has introduced a series of countermeasures to support affected
CROSS-STRAIT: The vast majority of Taiwanese support maintaining the ‘status quo,’ while concern is rising about Beijing’s influence operations More than eight out of 10 Taiwanese reject Beijing’s “one country, two systems” framework for cross-strait relations, according to a survey released by the Mainland Affairs Council (MAC) on Thursday. The MAC’s latest quarterly survey found that 84.4 percent of respondents opposed Beijing’s “one country, two systems” formula for handling cross-strait relations — a figure consistent with past polling. Over the past three years, opposition to the framework has remained high, ranging from a low of 83.6 percent in April 2023 to a peak of 89.6 percent in April last year. In the most recent poll, 82.5 percent also rejected China’s
PLUGGING HOLES: The amendments would bring the legislation in line with systems found in other countries such as Japan and the US, Legislator Chen Kuan-ting said Democratic Progressive Party (DPP) Legislator Chen Kuan-ting (陳冠廷) has proposed amending national security legislation amid a spate of espionage cases. Potential gaps in security vetting procedures for personnel with access to sensitive information prompted him to propose the amendments, which would introduce changes to Article 14 of the Classified National Security Information Protection Act (國家機密保護法), Chen said yesterday. The proposal, which aims to enhance interagency vetting procedures and reduce the risk of classified information leaks, would establish a comprehensive security clearance system in Taiwan, he said. The amendment would require character and loyalty checks for civil servants and intelligence personnel prior to
RSS